Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Avastin, while mainly used to treat cancer, works similarly to Eylea by blocking the vascular endothelial growth factor (VEGF) protein, which plays a key role in the formation of blood vessels.

Regulatory delays impacting EYLEA HD’s pre-filled syringe approval could hinder adoption. Increased market share of off-label Avastin poses a challenge to the anti-VEGF category. Analysts raised ...

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...

U.S. net sales of EYLEA were $736 million, down 39% year-over-year, impacted by increased use of off-label Avastin and lower wholesaler inventory levels. EYLEA HD sales reached $307 million ...

In September, for example, England’s High Court concluded that it is lawful to use Avastin in place of Lucentis and another VEGF drug, Bayer’s Eylea (aflibercept). Novartis and Roche launched ...

Consequently, low-cost off-label repackaged Avastin increased its anti-VEGF category share by approximately 6 percentage points to 32%. Despite these challenges, EYLEA HD and EYLEA captured 41% of ...

Avastin needs to be diluted and repackaged before ... Meanwhile, patents on both Lucentis and Eylea are due to expire in the US in 2020, raising the prospect of additional low-cost biosimilar ...

Eylea HD certainly also is one of the very strong ... So we are limiting these users for pretty much moving these patients who are on Avastin to switch them to either to Pavblu or Byooviz.

Sales of Avastin, approved for multiple oncology indications ... The drug posed stiff competition to Regeneron’s REGN ophthalmology drug Eylea. Regeneron has co-developed Eylea with Bayer.

Both standard Eylea and Eylea HD decreased ... Those other factors include pressure from Genentech’s Avastin, a lower net selling price, lower wholesale inventory and continued biosimilar pressure.